Free Newsletter
Should pharma pay the NIH royalties?
Free newsletter via e-mail
Tools
Looking past 2010, when more than $10 billion in fresh federal research funds runs out, the new head of the NIH is hatching a plan to gain a predictable flow of money to back an enlarged commitment to the country's researchers. And one way that the NIH could gain extra financial support, Dr. Francis Collins suggests, is by claiming a royalty from drugs that are developed following federally-supported research efforts. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
